Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.

Kangma (Shanghai) Biotechnology Co., Ltd., established on 2015-10-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of bio-based materials;Instrument sales;Sales of bio-based materials;Sales of Class I Medical Devices;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

RNAissance Ag is an ag biotechnology startup focused on delivering RNA-based insecticides for crop protection. RNA-based insecticides are environmentally friendly, and designed to be specific to particular target insects. They have a novel technology with a new mode of action. They will focus on developing spray-on RNA insecticides.

Seattle Children's Research Institute, the research division of Seattle Children's, was established in 2006. The research institute's campus encompasses 310,000 square feet in three buildings in downtown Seattle, near the heart of one of the nation’s most advanced biotechnology districts. The research institute has 588 staff members, including 249 principal investigators focusing on infectious disease, cancer, immunology and many other areas. Seattle Children's Research Institute is organized into nine interdisciplinary research centers: Center for Child Health, Behavior and Development Center for Childhood Cancer Research Center for Childhood Infections and Prematurity Research Center for Clinical and Translational Research Center for Developmental Therapeutics Center for Genetics and Development Center for Immunity and Immunotherapies Center for Integrative Brain Research Center for Developmental Biology and Regenerative Medicine In 2004, the Treuman Katz Center for Pediatric Bioethics was established and became the first bioethics program in the United States to focus on pediatrics issues with a broad mission of research, consultation, education and training.

Global Life Sciences Solutions USA LLC (doing business as Cytiva), part of Danaher Corp., is a company headquartered in Marlborough, MA, that manufactures therapeutics.\nThe company says this about itself: Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Shenzhen Progi Pharmaceutical Technology Co., Ltd., established on 2016-07-21, Business scope includes general business items:Biological product,medicine,medical instruments,Diagnostic reagents,Health products,food,cosmetic,electronic product,Technology development in information products and other fields,technical consulting,Technical Services,Technology transfer and product production and sales;Medical Research and Experimental Development(No restricted items);Import and export of goods and technology;plant,instrument,Leasing of machinery and equipment, etc.(Excluding finance lease),The licensing program is:Biological product,medicine,medical instruments,Diagnostic reagents,Health products,food,cosmetic,electronic product,Production of products in the field of information products, etc.;medicine,food sales.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Sichuan Lixinglong Environmental Protection Technology Co., Ltd., established on 2019-12-27, Business scope includes environmental protection equipment,Design of environmental protection software system and related accessories,develop,to develop,Technology transfer,Technical service and sales;Environmental Engineering,Water treatment project,Municipal public works professional contracting;Research and development of mechanical equipment,manufacturing and sales;Software development and sales;Production and sales of textile products;Environmental Engineering Design,consult;Machinery and Equipment Leasing;Recycling of renewable resources,processing(Does not contain solid waste,Hazardous Waste,Projects requiring approval from relevant departments, such as scrapped cars);General cargo;biotechnology research,Technology development and technical services;feed,Feed additive production;Sales:disinfection products,feed,Feed additives,fertilizer;goods,Technology Import and Export;Environmental Consulting;Municipal waste removal service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Teknologian Tutkimuskeskus VTT Oy provides technology solutions and innovation services. It offers its services in the sectors of bioeconomy, health and wellbeing, digital society, sustainable city, low carbon energy, technology industry, business development, and research infrastructure. The company was founded on January 16, 1942 and is headquartered in Espoo, Finland.

Shanghai Bangyao Biotechnology Co., Ltd., established on 2013-09-11, The scope of business includes engaging in biotechnology,Technology development in the field of medical science and technology,technical consulting,technology transfer,Technical Services,Laboratory equipment and consumables,Instrumentation,Class I medical device,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Equipment(Except special equipment),Sales of Electronics,Engaged in the import and export of goods and technology,software development,for-profit medical institution,pharmaceutical production. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Guangdong Wen's Group Co., Ltd. is a Chinese private company. The firm provides agriculture services.

Cugene develop medicines that harness the power of the human immune system to fight disease. Through innovative bioengineering, these novel therapeutics will provide specificity and efficacy while limiting unwanted side effects on neighboring healthy tissues.

Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.

R.J. Reynolds Tobacco Co. manufactures and markets tobacco products. The firm has tobacco-sheet manufacturing operations and a research-and-development facility in Winston-Salem. Its brands include Camel, Kool, Pall Mall, Winston, Doral, Barclay, Lucky Strike, and Monarch. The company was founded in 1875 and is headquartered in Winston-Salem, NC.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.